key Takeaways
- Ublituximab provides a cost-effective alternative without compromising treatment efficacy.
- Healthcare providers must balance cost considerations with individual patient needs.
- Ongoing monitoring and reporting of adverse effects remain crucial for patient safety.
The National Institute for Health and Care Excellence (NICE) has released new guidelines endorsing ublituximab (Briumvi) as a recommended treatment option for adults suffering from active relapsing multiple sclerosis (RMS). This decision comes after a thorough review of clinical evidence and cost-effectiveness analyses, setting a precedent for future treatment protocols.
NICE advises that ublituximab should be prescribed to adults diagnosed with relapsing-remitting multiple sclerosis, provided it aligns with the specified commercial arrangements. The guidelines emphasize selecting the most economical treatment among available options such as ocrelizumab and ofatumumab, taking into account factors like administration costs and dosage requirements. If the least expensive alternative proves unsuitable, healthcare providers are encouraged to explore other viable treatments.
Cost Efficiency and Clinical Effectiveness
Clinical data reveals that ublituximab outperforms teriflunomide in reducing relapse rates and matches the efficacy of other monoclonal antibodies like ocrelizumab and ofatumumab, all while offering a lower cost solution. The medication is available in 150-mg vials priced at £2,947, with confidential discounts applied under commercial agreements for NHS utilization.
Healthcare professionals are instructed to report any adverse reactions via the Yellow Card Scheme and adhere to the NHS Constitution’s guidelines on funding and health equity. The recommendations allow for the continuation of ublituximab treatment in patients already receiving it prior to the new guidance, ensuring stability in patient care without funding disruptions.
Tailoring treatment plans to meet individual patient needs emerges as a central theme in the newly released guidelines. This personalized approach ensures that while cost-effectiveness is prioritized, patient preferences and specific health circumstances are also taken into account.
Adopting ublituximab as a recommended treatment underscores NICE’s commitment to providing effective and affordable healthcare solutions. By emphasizing both clinical efficacy and economic viability, these guidelines aim to enhance the quality of life for patients with relapsing multiple sclerosis while maintaining sustainable healthcare practices.
Healthcare providers should stay informed about any updates to these recommendations, as NICE will revise the guidelines should new evidence emerge. Staying abreast of such changes ensures that patients receive the most current and effective treatments available, fostering an adaptable and responsive healthcare system.

This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.